A study revealed that Jun13296, a novel PLpro inhibitor, demonstrates potent antiviral and anti-inflammatory effects in vivo, offering hope for future COVID-19 therapies beyond Paxlovid. Study: Design ...
BioWorld - Tuesday, September 2, 2025 Breaking News: Trump administration impacts continue to roil the life sciences sector See today's BioWorld Science Home » University of Arizona describes new ...
As a result of vaccination or infection, our immune system produces antibodies that attach to the spike protein of SARS-CoV-2, preventing the virus from entering and replicating within cells. In ...
Children face over twice the risk of paediatric long COVID after SARS-CoV-2 reinfection, highlighting urgent needs for ...
Approximately 15 to 20 million Americans who have acquired COVID-19 experience persistent symptoms lasting over 3 months (long-COVID). Respiratory symptoms of long-COVID include breathlessness, ...
It’s that time of year: a thick, oppressive heat blankets everything, people huddle inside air-conditioned homes, offices, shops and cafes for respite—and COVID is surging again. Levels of SARS-CoV-2, ...
Rockefeller University has disclosed non-structural protein 3 (nsp3; PL-PRO) (SARS-CoV-2; COVID-19 virus) inhibitors reported to be useful for the treatment of SARS-CoV-2 infection (COVID-19).
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback